Allergan Botox Case Should Be Killed, Del. High Court Says

Law360, New York (April 5, 2013, 7:03 PM EDT) -- Delaware's Supreme Court on Friday reversed a controversial lower court decision that kept alive a derivative suit against Botox maker Allergan Inc., saying the case should have been tossed based on the dismissal of an almost-identical suit in California.

A five-judge panel said that Vice Chancellor J. Travis Laster erred in refusing to dismiss the suit, which targeted Allergan directors over alleged off-label marketing of the anti-wrinkle drug that led to a $600 million settlement with the U.S. Department of Justice. The high court said Vice...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.